Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at Wells Fargo & Company from $12.00 to $14.00. They now have an "equal weight" rating on the stock.
Zymeworks Inc. (NYSE: ZYME) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $18.00 price target on the stock.
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases [Yahoo! Finance]
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
Zymeworks Inc. (NYSE: ZYME) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.